<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881113477709</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881113477709</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lochmann van Bennekom</surname><given-names>Marc WH</given-names></name>
<xref ref-type="aff" rid="aff1-0269881113477709">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gijsman</surname><given-names>Harm J</given-names></name>
<xref ref-type="aff" rid="aff1-0269881113477709">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zitman</surname><given-names>Frans G</given-names></name>
<xref ref-type="aff" rid="aff2-0269881113477709">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881113477709"><label>1</label>Nijmegen Early Psychosis Program, Pro Persona Mental Health Care, Aurora, Nijmegen, the Netherlands</aff>
<aff id="aff2-0269881113477709"><label>2</label>Psychiatry, Leiden University Medical Centre, Leiden, the Netherlands</aff>
<author-notes>
<corresp id="corresp1-0269881113477709">Marc WH Lochmann van Bennekom, Pro Persona Mental Health Care, Aurora, Nijmegen Early Psychosis Program, Tarweweg 2, 6534 AM, Nijmegen, the Netherlands. Email: <email>m.lochmannvanbennekom@propersona.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>4</issue>
<fpage>327</fpage>
<lpage>336</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0269881113477709">
<title>Objective:</title>
<p>The purpose of this study was to review the scientific evidence for neurobiological rationale, efficacy, tolerability and cost effectiveness of antipsychotic polypharmacy (APP).</p>
</sec>
<sec id="section2-0269881113477709">
<title>Data sources:</title>
<p>A systematic literature search of Medline, Embase, Ovid and the Cochrane Database of Systematic Reviews until April 2012 was carried out.</p>
</sec>
<sec id="section3-0269881113477709">
<title>Results:</title>
<p>Theories behind APP have only modest pre-clinical and clinical evidence. We found limited statistical evidence supporting modest efficacy of APP in patients with psychotic symptoms refractory to clozapine. APP is associated with increased mortality, metabolic syndrome, decreased cognitive functioning, high dose prescription and non-adherence. It brings up extra costs, lacking evidence for cost-effectiveness.</p>
</sec>
<sec id="section4-0269881113477709">
<title>Conclusions:</title>
<p>Pre-clinical studies underpinning neurobiological hypotheses in APP are lacking. Evidence supporting efficacy of APP is limited with modest beneficial clinical relevance. APP is associated with several serious adverse effects and increased health costs. In the absence of more convincing pre-clinical support and clinical evidence we advise adherence to existing guidelines and limiting combinations of antipsychotics (in consideration with other pharmacotherapeutic, somatic and psychotherapeutic options) to patients with clozapine-refractory psychosis in well-evaluated individual trials that might need 10 weeks or more.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Antipsychotic polypharmacy</kwd>
<kwd>psychosis</kwd>
<kwd>efficacy</kwd>
<kwd>rationale</kwd>
<kwd>tolerability</kwd>
<kwd>cost-effectiveness</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-0269881113477709" sec-type="intro">
<title>Introduction</title>
<p>Antipsychotic polypharmacy (APP) is the concurrent use of two or more different antipsychotic agents by one patient. According to the definitions of the consensus meeting of the US National Association of State Mental Health Program Directors (<xref ref-type="bibr" rid="bibr54-0269881113477709">Medical Directors Council and State Medicaid Directors, 2001</xref>) it is an example of same class polypharmacy and, depending on prescribed co-medication, a more or less substantial part of total polypharmacy in a patient.</p>
<p>The prevalence of APP is high, considering guidelines advocating antipsychotic monotherapy and limiting APP as an option in clozapine-refractory psychotic patients (<xref ref-type="bibr" rid="bibr1-0269881113477709">American Psychiatric Association, 2004</xref>; <xref ref-type="bibr" rid="bibr59-0269881113477709">Moore et al., 2007</xref>; <xref ref-type="bibr" rid="bibr62-0269881113477709">National Institute for Clinical Excellence, 2009</xref>). Relative short term (&lt;2 months) APP is reported in 5–42% (<xref ref-type="bibr" rid="bibr8-0269881113477709">Broekema et al., 2007</xref>; <xref ref-type="bibr" rid="bibr11-0269881113477709">Chakos et al., 2006</xref>) and long term (≥1 year) APP in approximately 13% of patients on antipsychotic treatment (<xref ref-type="bibr" rid="bibr5-0269881113477709">Barbui et al., 2006</xref>). In a large study by Gallego and colleagues, the overall prevalence rate of APP across decades and global regions was 19.6%. They also found that APP since the 1980s has increased in the US from 12.7% to 17%, increased in Oceania from 2% to 17%, fluctuated in Europe between 19% and 24%, but markedly decreased in Asia from 55.5% to 19.2% (<xref ref-type="bibr" rid="bibr32-0269881113477709">Gallego et al., 2012</xref>). Besides differences in region and year of study, the large variety in prevalence rates across studies is also due to methodological differences such as setting, inclusion or exclusion of low potency antipsychotics and as-required (‘p.r.n.’) antipsychotics, and duration of antipsychotic co-prescription thus ruling in or out APP during cross-over switching of antipsychotics.</p>
<p>Findings that more than one-third (<xref ref-type="bibr" rid="bibr40-0269881113477709">Howes et al., 2012</xref>) or even up to 65% (<xref ref-type="bibr" rid="bibr84-0269881113477709">Taylor et al., 2003</xref>) of patients on clozapine have previously received non-clozapine APP, and that in only 4% of patients on APP a previous trial of clozapine was commenced (<xref ref-type="bibr" rid="bibr50-0269881113477709">Langan and Shajahan, 2010</xref>) suggest that adherence to existing guidelines is insufficient. This may contribute to an inappropriate delay of clozapine treatment lasting up to 4–5 years (<xref ref-type="bibr" rid="bibr40-0269881113477709">Howes et al., 2012</xref>; <xref ref-type="bibr" rid="bibr84-0269881113477709">Taylor et al., 2003</xref>). Short-term APP can be appropriate while cross-tapering in a process of switching antipsychotics. Persistent APP can be part of a pharmacotherapeutic strategy but also the unintended result of unfinished cross-titration in a process of switching antipsychotics (<xref ref-type="bibr" rid="bibr16-0269881113477709">Chong and Remington, 2000</xref>; <xref ref-type="bibr" rid="bibr72-0269881113477709">Sernyak and Rosenheck, 2004</xref>; <xref ref-type="bibr" rid="bibr76-0269881113477709">Stahl, 1999</xref>).</p>
<p>High APP prescribers have more clinical experience, less concern about APP and are more likely to prescribe a preferred combination of antipsychotics, although no overall preferred strategy emerged. Both high and low APP prescribers have ‘inherited’ most of their APP cases from their colleagues and are reluctant to switch patients to antipsychotic monotherapy (<xref ref-type="bibr" rid="bibr21-0269881113477709">Correll et al., 2011</xref>). Psychiatrists who are sceptical towards evidence-based guidelines or algorithms more often use APP and prescribe excessive doses of antipsychotics (<xref ref-type="bibr" rid="bibr41-0269881113477709">Ito et al., 2005</xref>). The most important clinical reasons for APP are refractory psychotic symptoms by increasing D<sub>2</sub>-antagonism, reducing negative symptoms (dominantly by adding an atypical to a conventional antipsychotic), reducing multi-class polypharmacy, and extrapyramidal symptoms (<xref ref-type="bibr" rid="bibr72-0269881113477709">Sernyak and Rosenheck, 2004</xref>). Incidentally it is used to manage side effects of the primary antipsychotic agent (<xref ref-type="bibr" rid="bibr28-0269881113477709">Fleischhacker et al., 2010</xref>; <xref ref-type="bibr" rid="bibr74-0269881113477709">Shim et al., 2007</xref>) Patient factors associated with APP are long duration of illness, frequent previous psychiatric hospitalizations and marked thought disorders at admission (<xref ref-type="bibr" rid="bibr42-0269881113477709">Janssen et al., 2004</xref>).</p>
<p>Important building blocks of high-quality, effective and safe health care delivery are basic neurobiological science, its translation into clinical research on efficacy, effectiveness and tolerability and, finally, the adoption of clinical guidelines that can be implemented in a cost-effective way (<xref ref-type="bibr" rid="bibr23-0269881113477709">Dougherty and Conway, 2008</xref>; <xref ref-type="bibr" rid="bibr37-0269881113477709">Honer et al., 2009</xref>). There are serious concerns that in APP this is not the case, making it ‘psychiatry’s dirty little secret’ (<xref ref-type="bibr" rid="bibr76-0269881113477709">Stahl, 1999</xref>). In this paper, we review the scientific evidence for (a) the neurobiological mechanisms of APP, (b) its efficacy, (c) tolerability and (d) cost-effectiveness. We conclude with an integrative discussion, give clinical suggestions and propose directions for future research.</p>
</sec>
<sec id="section6-0269881113477709" sec-type="methods">
<title>Methods</title>
<p>Medline, Embase, Ovid and the Cochrane Database of Systematic Reviews were searched until April 2012. The search was performed by using the following search terms: schizophrenia AND antipsychotic* AND ‘antipsychotic polypharmacy’ OR ‘antipsychotic combination’ OR ‘antipsychotic augmentation’ OR ‘antipsychotic add on’ OR ‘antipsychotic co-prescription’ in title and/or abstract. Limitations were set to humans and (young) adults/middle aged. Out of the resulting 177 articles, relevant publications were extracted using following search terms:</p>
<list id="list1-0269881113477709" list-type="simple">
<list-item><p>For data on neurobiological rationale: ‘neurobiology’ OR ‘neurobiological rationale’ OR ‘mechanism of action’</p></list-item>
<list-item><p>For data on efficacy: ‘efficacy’ OR ‘effectiveness’ AND ‘systematic review’ OR ‘meta-analysis’.</p></list-item>
<list-item><p>For data on tolerability: ‘tolerability’ OR ‘drug safety’ OR ‘adverse drug event’</p></list-item>
<list-item><p>For data on cost-effectiveness: ‘cost effectiveness’ OR ‘cost benefit analysis’</p></list-item>
</list>
<p>Reference lists from retrieved articles were reviewed for relevant studies to complete this literature search.</p>
</sec>
<sec id="section7-0269881113477709" sec-type="results">
<title>Results</title>
<sec id="section8-0269881113477709">
<title>Neurobiological mechanism</title>
<p>Combining antipsychotics should be based on neurobiological knowledge of mechanism of action. The neurobiological rationale of combining antipsychotics is mostly based on one or more of the following hypotheses (<xref ref-type="bibr" rid="bibr29-0269881113477709">Freudenreich and Goff, 2002</xref>):</p>
<list id="list2-0269881113477709" list-type="order">
<list-item><p>Dopamine hypothesis</p></list-item>
<list-item><p>Serotonin hypothesis</p></list-item>
<list-item><p>Receptor binding profiles</p></list-item>
</list>
<sec id="section9-0269881113477709">
<title>Dopamine hypothesis</title>
<p>The dopamine hypothesis postulates that psychotic symptoms are the result of mesolimbic dopaminergic hyperactivity. Antipsychotics have D<sub>2</sub>-antagonistic properties, thus diminishing mesolimbic hyperdopaminergic state and reducing psychotic symptoms (<xref ref-type="bibr" rid="bibr56-0269881113477709">Meltzer and Stahl, 1976</xref>). It is assumed that antipsychotics are most effective and have the least side effects with D<sub>2</sub> receptor occupancy of 70–80%. Combination of an antipsychotic with relative weak D<sub>2</sub> receptor binding properties (like clozapine or quetiapine) and an agent with strong D<sub>2</sub> binding (like haloperidol or risperidone) or selective D<sub>2</sub> binding (like sulpiride or amisulpride) theoretically can result in optimal 70–80% D<sub>2</sub> receptor occupancy (<xref ref-type="bibr" rid="bibr71-0269881113477709">Seeman and Tallerico, 1998</xref>). Clozapine augmentation studies with sulpiride, amisulpride and risperidone are based on this theory (<xref ref-type="bibr" rid="bibr2-0269881113477709">Anil Yagcioglu et al., 2005</xref>; <xref ref-type="bibr" rid="bibr34-0269881113477709">Genc et al., 2007</xref>; <xref ref-type="bibr" rid="bibr73-0269881113477709">Shiloh et al., 1997</xref>). However, the scientific evidence supporting this neurobiological theory is limited. Preclinical studies investigating the effect of combinations of antipsychotics in animal models are sparse (<xref ref-type="bibr" rid="bibr37-0269881113477709">Honer et al., 2009</xref>). There is some pre-clinical evidence for a beneficial effect of amperozide (a putative antipsychotic compound) in combination with haloperidol on conditioned avoidance response and food-reinforced lever-pressing tasks in rats, suggesting therapeutic value in the treatment of psychotic disorders (<xref ref-type="bibr" rid="bibr24-0269881113477709">Egbe et al., 1990</xref>). In a clinical single-photon emission computed tomography (SPECT) study, the addition of 4 mg haloperidol in six patients using 450–500 mg clozapine daily actually resulted in increased D<sub>2</sub> receptor occupancies from 21.2% (standard deviation (SD) 17.1) at baseline to 65.3% (SD 22.6) after 10 weeks in the haloperidol-group (<italic>n</italic>=2) compared with 22.8% (SD 8.44) to 21.0% (SD 14) in the control group (<italic>n</italic>=4), however without significant clinical improvement (<xref ref-type="bibr" rid="bibr60-0269881113477709">Mossaheb et al., 2006</xref>). On the other hand, a small clinical magnetic resonance imaging (MRI) study in five patients demonstrated that four weeks addition of 4 mg of haloperidol to five patients using 225–500 mg clozapine actually resulted in increased D<sub>2</sub> receptor occupancy from 55% to 79%, similar to haloperidol monotherapy (<xref ref-type="bibr" rid="bibr45-0269881113477709">Kapur et al., 2001</xref>). The level of D<sub>2</sub> receptor occupancy in the last week was related to the plasma level of haloperidol, rather than to the plasma level of clozapine. This might implicate that in APP the antipsychotic with the weakest D<sub>2</sub> binding (clozapine) is replaced by the agent with the strongest D<sub>2</sub> affinity (<xref ref-type="bibr" rid="bibr82-0269881113477709">Taylor and Smith, 2009</xref>). This hypothesis is supported by a SPECT study that found that amisulpride augmentation to clozapine increased D<sub>2</sub> receptor occupancy but not to the extent expected (<xref ref-type="bibr" rid="bibr53-0269881113477709">Matthiasson et al., 2003</xref>).</p>
</sec>
<sec id="section10-0269881113477709">
<title>Serotonin hypothesis</title>
<p>Serotonin is thought to play a role in the pathophysiology of schizophrenia. In a highly simplified model, antagonism of the 5HT<sub>2A</sub> receptor blocks the inhibiting effect of the serotonergic system on dopamine release in the medial prefrontal cortex, improving signal-to-noise-ratio and restoring prefrontal cortical functioning with positive effects on cognition and negative symptoms (<xref ref-type="bibr" rid="bibr22-0269881113477709">Di Pietro and Seamans, 2007</xref>). Second generation antipsychotics (SGAs) have antagonistic properties on both D<sub>2</sub> receptor and (amongst others) the 5HT2<sub>2A</sub> receptor, using this mediating effect. A 5HT<sub>2A</sub>/D<sub>2</sub>-ratio &gt;1 is typical for these agents (<xref ref-type="bibr" rid="bibr55-0269881113477709">Meltzer et al., 1989</xref>). APP consisting of the combination of a first generation antipsychotic (FGA) and a SGA drug is based on this serotonin hypothesis in treating negative symptoms. However, we found no in vivo or in vitro studies investigating the combined effect of FGAs and SGAs on prefrontal cortical dopamine balance.</p>
</sec>
<sec id="section11-0269881113477709">
<title>Receptor binding profiles</title>
<p>Theoretically, combining antipsychotics with different receptor binding profiles can be an attempt to mimic the broad receptor binding profile of clozapine, a superior agent in the treatment of refractory positive or negative symptoms (<xref ref-type="bibr" rid="bibr29-0269881113477709">Freudenreich and Goff, 2002</xref>). It can also aim to reduce the expression of side effects of each of the individual agents at the same level of cumulative D<sub>2</sub> receptor blocking. However, we found no evidence supporting these hypotheses.</p>
</sec>
<sec id="section12-0269881113477709">
<title>In summary</title>
<p>The overall conclusion is that all of these hypotheses on combining antipsychotics are empirically insufficiently supported, lacking robust preclinical or clinical data.</p>
</sec>
</sec>
<sec id="section13-0269881113477709">
<title>Efficacy</title>
<p>Efficacy of combining antipsychotics needs to be demonstrated in high quality research, preferably systematic reviews and meta-analyses of randomized controlled trials (RCTs). Therefore, we limited our literature search to these publication types, which yielded seven systematic reviews. We excluded one review (<xref ref-type="bibr" rid="bibr17-0269881113477709">Cipriani et al., 2010</xref>) that did not have a control condition of antipsychotic monotherapy, leaving six reviews analyzing 40 publications on efficacy of APP. These 40 publications consisted of 33 (blinded or unblinded) RCTs studying combinations of clozapine with a second antipsychotic and seven (blinded or unblinded) RCTs with non-clozapine antipsychotic combinations. Twenty-two of these studies were conducted in Asia, including 17 studies from China. <xref ref-type="table" rid="table1-0269881113477709">Table 1</xref> provides an overview of the main characteristics of all reviewed publications and the systematic reviews that included them.</p>
<table-wrap id="table1-0269881113477709" position="float">
<label>Table 1.</label>
<caption>
<p>Main characteristics of all reviewed publications and the systematic reviews that included them.</p>
</caption>
<graphic alternate-form-of="table1-0269881113477709" xlink:href="10.1177_0269881113477709-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Study</th>
<th align="left">Country</th>
<th align="left">DB</th>
<th align="left">Pl</th>
<th align="left"><italic>n</italic> (I/C)</th>
<th align="left">Comparison</th>
<th align="left">Dur.</th>
<th align="left">Outcome (+/−)</th>
<th align="left" colspan="6">Included in review by<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="left"><xref ref-type="bibr" rid="bibr66-0269881113477709">Paton et al., 2007</xref></th>
<th align="left"><xref ref-type="bibr" rid="bibr6-0269881113477709">Barbui et al., 2009</xref></th>
<th align="left"><xref ref-type="bibr" rid="bibr82-0269881113477709">Taylor and Smith, 2009</xref></th>
<th align="left"><xref ref-type="bibr" rid="bibr20-0269881113477709">Correll et al., 2009</xref></th>
<th align="left"><xref ref-type="bibr" rid="bibr87-0269881113477709">Wang et al., 2010</xref></th>
<th align="left"><xref ref-type="bibr" rid="bibr83-0269881113477709">Taylor et al., 2012</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td/>
<td colspan="2">RCTs involving clozapine combinations</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> 1</td>
<td>(<xref ref-type="bibr" rid="bibr2-0269881113477709">Anil Yagcioglu et al., 2005</xref>)</td>
<td>Turkey</td>
<td>Y</td>
<td>Y</td>
<td>30 (16/14)</td>
<td>CLZ + RIS vs CLZ</td>
<td>6 w</td>
<td>+ (PANSS)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
</tr>
<tr>
<td> 2</td>
<td>(<xref ref-type="bibr" rid="bibr3-0269881113477709">Assion et al., 2008</xref>)</td>
<td>Germany</td>
<td>Y</td>
<td>Y</td>
<td>16 (13/3)</td>
<td>CLZ + AMISUL (400/600 mg/d) vs CLZ</td>
<td>6 w</td>
<td>– (BPRS)<break/>(600 mg + on sec. outcome CGI, GAF, MADRS)</td>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td> 3</td>
<td>(<xref ref-type="bibr" rid="bibr10-0269881113477709">Cha et al., 1999</xref>)</td>
<td>China</td>
<td>N</td>
<td>N</td>
<td>200 (100/100)</td>
<td>CLZ + CPZ vs CLZ</td>
<td>6 w</td>
<td>+ (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> 4</td>
<td>(<xref ref-type="bibr" rid="bibr12-0269881113477709">Chang et al., 2008</xref>)</td>
<td>Korea</td>
<td>Y</td>
<td>Y</td>
<td>62 (30/32)</td>
<td>CLZ + ARI vs CLZ</td>
<td>8 w</td>
<td>– (BPRS)</td>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td> 5</td>
<td>(<xref ref-type="bibr" rid="bibr27-0269881113477709">Fleischhacker et al., 2008</xref>)</td>
<td>Austria, Finland, France, UK, US</td>
<td>Y</td>
<td>Y</td>
<td>207 ( 108/99)</td>
<td>CLZ + ARI vs CLZ</td>
<td>16 w</td>
<td>– (PANSS)</td>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td> 6</td>
<td>(<xref ref-type="bibr" rid="bibr30-0269881113477709">Freudenreich et al., 2007</xref>)</td>
<td>US</td>
<td>Y</td>
<td>Y</td>
<td>24 (11/13)</td>
<td>CLZ + RIS vs CLZ</td>
<td>6 w</td>
<td>– (PANSS)</td>
<td/>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
</tr>
<tr>
<td> 7</td>
<td>(<xref ref-type="bibr" rid="bibr31-0269881113477709">Friedman et al., 2011</xref>)</td>
<td>US</td>
<td>Y</td>
<td>Y</td>
<td>53 (25/28)</td>
<td>CLZ + PIM vs CLZ</td>
<td>12 w</td>
<td>– (PANSS)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td> 8</td>
<td>(<xref ref-type="bibr" rid="bibr38-0269881113477709">Honer et al., 2006</xref>)</td>
<td>Canada, Germany, China, UK</td>
<td>Y</td>
<td>Y</td>
<td>68 (34/34)</td>
<td>CLZ + RIS vs CLZ</td>
<td>18 w</td>
<td>– (PANSS)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
</tr>
<tr>
<td> 9</td>
<td>(<xref ref-type="bibr" rid="bibr43-0269881113477709">Jia et al., 2000</xref>)</td>
<td>China</td>
<td>N</td>
<td>N</td>
<td>50 (26/24)</td>
<td>CLZ + PIP vs CLZ</td>
<td>12 w</td>
<td>+ (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>10</td>
<td>(<xref ref-type="bibr" rid="bibr44-0269881113477709">Josiassen et al., 2005</xref>)</td>
<td>US</td>
<td>Y</td>
<td>Y</td>
<td>40 (20/20)</td>
<td>CLZ + RIS vs CLZ</td>
<td>12 w</td>
<td>+ (BPRS)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
</tr>
<tr>
<td>11</td>
<td>(<xref ref-type="bibr" rid="bibr49-0269881113477709">Kreinin et al., 2006</xref>)</td>
<td>Israel</td>
<td>Y</td>
<td>Y</td>
<td>40 (20/20)</td>
<td>CLZ + AMISUL vs CLZ</td>
<td>3 w</td>
<td>– (PANSS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>12</td>
<td>(<xref ref-type="bibr" rid="bibr52-0269881113477709">Liu et al., 1996</xref>)</td>
<td>China</td>
<td>N</td>
<td>N</td>
<td>63 (31/32)</td>
<td>CLZ + SUL vs CLZ</td>
<td>12 w</td>
<td>+ (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>13</td>
<td>(<xref ref-type="bibr" rid="bibr51-0269881113477709">Liu and Li, 2001</xref>)</td>
<td>China</td>
<td>N</td>
<td>N</td>
<td>64 (32/32)</td>
<td>CLZ + RIS vs CLZ</td>
<td>10 w</td>
<td>– (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>14</td>
<td>(<xref ref-type="bibr" rid="bibr60-0269881113477709">Mossaheb et al., 2006</xref>)</td>
<td>Austria</td>
<td>Y</td>
<td>Y</td>
<td>6 (2/4)</td>
<td>CLZ + HAL</td>
<td>10 w</td>
<td>– (PANSS)</td>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td>15</td>
<td>(<xref ref-type="bibr" rid="bibr61-0269881113477709">Muscatello et al., 2011</xref>)</td>
<td>Italy</td>
<td>Y</td>
<td>Y</td>
<td>40 (20/20)</td>
<td>CLZ + ARI vs CLZ</td>
<td>24 w</td>
<td>+ (BPRS, SAPS, SANS)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td>16</td>
<td>(<xref ref-type="bibr" rid="bibr63-0269881113477709">Ni et al., 2001</xref>)</td>
<td>China?</td>
<td>N</td>
<td>N</td>
<td>215 (109/106)</td>
<td>CLZ + RIS vs CLZ</td>
<td>8 w</td>
<td>+ (PANSS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>17</td>
<td>(<xref ref-type="bibr" rid="bibr64-0269881113477709">Nielsen et al., 2012</xref>)</td>
<td>Denmark</td>
<td>Y</td>
<td>Y</td>
<td>50 (25/25)</td>
<td>CLZ + SER vs CLZ</td>
<td>12 w</td>
<td>– (PANSS)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td>18</td>
<td>(<xref ref-type="bibr" rid="bibr67-0269881113477709">Peng et al., 2001</xref>)</td>
<td>China?</td>
<td>N</td>
<td>N</td>
<td>66 (32/34)</td>
<td>CLZ + RIS vs CLZ</td>
<td>8 w</td>
<td>– (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>19</td>
<td>(<xref ref-type="bibr" rid="bibr68-0269881113477709">Potter et al., 1989</xref>)</td>
<td>China</td>
<td>N</td>
<td>Y</td>
<td>37 (20/17)</td>
<td>CLZ + CPZ vs CLZ</td>
<td>8 w</td>
<td>– (BPRS)</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
</tr>
<tr>
<td>20</td>
<td>(<xref ref-type="bibr" rid="bibr73-0269881113477709">Shiloh et al., 1997</xref>)</td>
<td>Israel</td>
<td>Y</td>
<td>Y</td>
<td>28 (16/12)</td>
<td>CLZ + SUL vs CLZ</td>
<td>10 w</td>
<td>+ (BPRS)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>21</td>
<td>(<xref ref-type="bibr" rid="bibr75-0269881113477709">Si and Yuan, 1999</xref>)</td>
<td>China</td>
<td>N</td>
<td>N</td>
<td>100 (50/50)</td>
<td>CLZ + SUL vs CLZ</td>
<td>12w</td>
<td>– (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>22</td>
<td>(<xref ref-type="bibr" rid="bibr88-0269881113477709">Wang et al., 1994</xref>)</td>
<td>China</td>
<td>?</td>
<td>N</td>
<td>70 (36/34)</td>
<td>CLZ + SUL vs CLZ</td>
<td>8 w</td>
<td>+ (PANSS)</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td/>
</tr>
<tr>
<td>23</td>
<td>(<xref ref-type="bibr" rid="bibr89-0269881113477709">Weiner et al., 2010</xref>)</td>
<td>US</td>
<td>Y</td>
<td>Y</td>
<td>69 (33/36)</td>
<td>CLZ + RIS vs CLZ</td>
<td>16 w</td>
<td>– (BPRS)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>X</td>
</tr>
<tr>
<td>24</td>
<td>(<xref ref-type="bibr" rid="bibr93-0269881113477709">Wu, 2002</xref>)</td>
<td>China?</td>
<td>N</td>
<td>N</td>
<td>67 (33/34)</td>
<td>CLZ + RIS vs CLZ</td>
<td>12 w</td>
<td>– (PANSS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>25</td>
<td>(<xref ref-type="bibr" rid="bibr94-0269881113477709">Xao, 1999</xref>)</td>
<td>China?</td>
<td>N</td>
<td>N</td>
<td>41 (20/21)</td>
<td>CLZ + SUL vs CLZ</td>
<td>6 w</td>
<td>+ (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>26</td>
<td>(<xref ref-type="bibr" rid="bibr95-0269881113477709">Xie and Ni, 2001</xref>)</td>
<td>China</td>
<td>Y</td>
<td>?</td>
<td>40 (20/20)</td>
<td>CLZ + RIS vs CLZ</td>
<td>8 w</td>
<td>– (scale?)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>27</td>
<td>(<xref ref-type="bibr" rid="bibr96-0269881113477709">Xin et al., 2001</xref>)</td>
<td>China?</td>
<td>N</td>
<td>N</td>
<td>64 (32/32)</td>
<td>CLZ + RIS vs CLZ.</td>
<td>12 w</td>
<td>– (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>28</td>
<td>(<xref ref-type="bibr" rid="bibr97-0269881113477709">Xu, 2006</xref>)</td>
<td>China</td>
<td>?</td>
<td>N</td>
<td>64 (32/32)</td>
<td>CLZ + SULP vs CLZ</td>
<td>8 w</td>
<td>– (SANS)</td>
<td/>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
</tr>
<tr>
<td>29</td>
<td>(<xref ref-type="bibr" rid="bibr99-0269881113477709">Yue et al., 2004</xref>)</td>
<td>China?</td>
<td>N</td>
<td>N</td>
<td>46 (19/27)</td>
<td>CLZ + RIS vs CLZ</td>
<td>96 w</td>
<td>– (PANSS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>30</td>
<td>(<xref ref-type="bibr" rid="bibr100-0269881113477709">Zhang and Xu, 1989</xref>)</td>
<td>China</td>
<td>Y</td>
<td>?</td>
<td>37 (20/17)</td>
<td>CLZ + CPZ vs CLZ</td>
<td>8 w</td>
<td>– (BPRS ?)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>31</td>
<td>(<xref ref-type="bibr" rid="bibr102-0269881113477709">Zhu and Deng, 2002</xref>)</td>
<td>China ?</td>
<td>N</td>
<td>N</td>
<td>84 (42/42)</td>
<td>CLZ + PIP vs CLZ</td>
<td>24 w</td>
<td>+ (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>32</td>
<td>(<xref ref-type="bibr" rid="bibr103-0269881113477709">Zhu et al., 1999</xref>)</td>
<td>China ?</td>
<td>N</td>
<td>N</td>
<td>59 (29/30)</td>
<td>CLZ + SUL vs CLZ</td>
<td>12 w</td>
<td>– (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td>X</td>
<td/>
</tr>
<tr>
<td>33</td>
<td>(<xref ref-type="bibr" rid="bibr104-0269881113477709">Zou et al., 2003</xref>)</td>
<td>China ?</td>
<td>N</td>
<td>N</td>
<td>61 (30/31)</td>
<td>CLZ + SUL vs CLZ.</td>
<td>12 w</td>
<td>– (BPRS)</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td colspan="2">RCTs involving non-clozapine combinations</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>34</td>
<td>(<xref ref-type="bibr" rid="bibr7-0269881113477709">Barrett et al., 1957</xref>)</td>
<td>US</td>
<td>Y</td>
<td>Y</td>
<td>30 (10/10/10)</td>
<td>RES + CPZ vs RES<break/>RES + CPZ vs CPZ</td>
<td>12 w</td>
<td>– (scale ?)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>35</td>
<td>(<xref ref-type="bibr" rid="bibr14-0269881113477709">Chien and Cole, 1973</xref>)</td>
<td>US</td>
<td>N</td>
<td>N</td>
<td>46 (15/15/16)</td>
<td>CPZ+ FLU vs CPZ<break/>CPZ + FLU vs FLU</td>
<td>4 w</td>
<td>+ (scale ?)<break/>– (scale ?)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>36</td>
<td>(<xref ref-type="bibr" rid="bibr36-0269881113477709">Higashima et al., 2004</xref>)</td>
<td>Japan</td>
<td>N</td>
<td>N</td>
<td>19 (9/10)</td>
<td>HAL + LEV vs HAL</td>
<td>8 w</td>
<td>+ (agitation)<break/>– (pos/neg sympt<break/>(BPRS)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>37</td>
<td>(<xref ref-type="bibr" rid="bibr48-0269881113477709">Kotler et al., 2004</xref>)</td>
<td>Israel</td>
<td>N</td>
<td>N</td>
<td>17 (9/8)</td>
<td>OLZ + SUL vs OLZ</td>
<td>8 w</td>
<td>– (PANSS)<break/>+ (HAM-D)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>38</td>
<td>(<xref ref-type="bibr" rid="bibr65-0269881113477709">Nishikawa et al., 1985</xref>)</td>
<td>Japan</td>
<td>Y</td>
<td>N</td>
<td>93 (47/24/22)</td>
<td>PIM + THI vs PIM<break/>PIM + THI vs THI</td>
<td>52 w</td>
<td>+<break/>+<break/>(number of symptom free days, no scale)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>39</td>
<td>(<xref ref-type="bibr" rid="bibr81-0269881113477709">Talbot, 1964</xref>)</td>
<td>US</td>
<td>Y</td>
<td>Y</td>
<td>77 (27/25/25)</td>
<td>CPZ + TRI vs CPZ<break/>CPZ + TRI vs TRI</td>
<td>32 w</td>
<td>+<break/>+<break/>(no scale)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>40</td>
<td>(<xref ref-type="bibr" rid="bibr98-0269881113477709">Yagi, 1976</xref>)</td>
<td>Japan</td>
<td>Y</td>
<td>Y</td>
<td>233 (116/117)</td>
<td>CPZ + PER vs CPZ</td>
<td>17 w</td>
<td>– (Keio Psychiatric Rating Scale for Schizophrenia, Keio Behavioral Rating Scale and general improvement rating)</td>
<td/>
<td/>
<td/>
<td>X</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881113477709">
<p>AMISUL: amisulpride; ARI: aripiprazole; BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impressions scale; CLZ: clozapine; CPZ: chlorpromazine; DB: double blind; Dur.: trial duration; FLU: fluphenazine; GAF: Global Assessment of Functioning; HAL: haloperidol; HAM-D: Hamilton Depression Rating Scale; LEV: levomepromazine; MADRS: Montgomery Åsberg Depression Rating Scale; <italic>n</italic> (I/C): total participants (number allocated to intervention arm/number allocated to control arm); N: no; OLZ: olanzapine; Outcome (+/−): +: intervention significant superior; –: intervention not significant superior; PANSS: Positive and Negative Syndrome Scale; PER: perphenazine; Pl: placebo controlled; PIM: pimozide; PIP: pipothiazine; RCT: Randomized Controlled Trial; RES: reserpine; RIS: risperidone; SANS: Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; SER: sertindole; SUL: sulpiride; THI: thioridazine; TRI: trifluoperazine; Y: yes; ?: unclear.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In <xref ref-type="table" rid="table2-0269881113477709">Table 2</xref> we summarize characteristics and outcome of the six systematic reviews included in this paper.</p>
<table-wrap id="table2-0269881113477709" position="float">
<label>Table 2.</label>
<caption>
<p>Summary of six systematic reviews studying efficacy of antipsychotic combinations in schizophrenia.</p>
</caption>
<graphic alternate-form-of="table2-0269881113477709" xlink:href="10.1177_0269881113477709-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left"><italic>n</italic></th>
<th align="left"><italic>N</italic></th>
<th align="left">Included studies</th>
<th align="left">Intervention vs comparison</th>
<th align="left">Outcome</th>
<th align="left">Efficacy dichotomous outcome: RR (95% CI) (study-defined inefficacy)</th>
<th align="left">Efficacy<break/>continuous outcome:<break/>SMD (95% CI) (change on rating scale)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(<xref ref-type="bibr" rid="bibr6-0269881113477709">Barbui, et al., 2009</xref>)</td>
<td>21</td>
<td>1480</td>
<td>(Un)blinded RCTs in clozapine treated schizophrenia</td>
<td>CLZ + any AP<break/>vs<break/>CLZ</td>
<td>Dichotomous: Response (≥20 or ≥30% reduction on PANSS/BPRS)<break/>Continuous:<break/>score on PANSS/BPRS</td>
<td>Open RCTs:<break/>0.64 (0.42 to 0.97)<break/>Double blind RCTs:<break/>0.91 (0.75 to 1.11)</td>
<td>Open RCTs:<break/>−0.80 (−1.14 to −0.46)<break/>Double blind RCTs:<break/>−0.12 (−0.57 to 0.32)</td>
</tr>
<tr>
<td>(<xref ref-type="bibr" rid="bibr20-0269881113477709">Correll et al., 2009</xref>)</td>
<td>19</td>
<td>1216</td>
<td>(Un)blinded RCTs in schizophrenia</td>
<td>Any AP (incl. CLZ) + any AP<break/>vs<break/>any AP (incl. CLZ)</td>
<td>Dichotomous: Response (≥50% reduction on PANSS/BPRS, ‘much better’ on CGI)</td>
<td>0.76 (0.63 to 0.90)</td>
<td/>
</tr>
<tr>
<td>(<xref ref-type="bibr" rid="bibr66-0269881113477709">Paton et al., 2007</xref>)</td>
<td>4</td>
<td>166</td>
<td>(Un)blinded RCTs in clozapine-treated schizophrenia</td>
<td>CLZ + any AP<break/>vs<break/>CLZ</td>
<td>Dichotomous: Response (≥20% reduction on PANSS/BPRS)</td>
<td>Trial duration ≥10 w:<break/>0.22 (0.07 to 0.72)<sup>a</sup> Trial duration &lt;10 w:<break/>1.69 (0.76 to 3.70)</td>
<td/>
</tr>
<tr>
<td>(<xref ref-type="bibr" rid="bibr82-0269881113477709">Taylor and Smith, 2009</xref>)</td>
<td>10</td>
<td>522</td>
<td>Blinded RCTs in clozapine-treated schizophrenia</td>
<td>CLZ + any AP<break/>vs<break/>CLZ</td>
<td>Continuous:<break/>score on PANSS/BPRS</td>
<td/>
<td>−0.180 (−0.356 to −0.004)</td>
</tr>
<tr>
<td>(<xref ref-type="bibr" rid="bibr83-0269881113477709">Taylor et al., 2012</xref>)</td>
<td>14</td>
<td>734</td>
<td>Blinded RCTs in clozapine-treated schizophrenia</td>
<td>CLZ + any AP<break/>vs<break/>CLZ</td>
<td>Continuous:<break/>score on PANSS/BPRS</td>
<td/>
<td>Overall<break/>−0.239 (−0.452 to −0.026)<break/>Trial duration ≥10 w<break/>−0.223 (−0.432 to −0.015)<break/>Trial duration &lt;10 w<break/>−0.103 (−0.365 to 0.158)</td>
</tr>
<tr>
<td>(<xref ref-type="bibr" rid="bibr87-0269881113477709">Wang et al., 2010</xref>)</td>
<td>4</td>
<td>221</td>
<td>(Un)blinded RCTs in schizophrenia and schizophrenia-like psychosis</td>
<td>Any AP (incl. CLZ) + sulpiride<break/>vs<break/>any AP (incl. CLZ)</td>
<td>Dichotomous: Clinically important response in global state</td>
<td>Trial duration &lt;12 w:<break/>0.58 (0.3 to 1.09)<break/>Trial duration &gt;26 w:<break/>0.67 (0.42 to 1.08)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0269881113477709">
<p>AP: antipsychotic; BPRS: Brief Psychiatric Rating Scale; CGI: Clinical Global Impression scale; CI: confidence interval; CLZ: clozapine; <italic>n</italic>: number of studies, <italic>N</italic>: number of participants; PANSS: Positive And Negative Syndrome Scale; RCT: randomized controlled trial; RR: relative risk; SMD: standardized mean difference; <sup>a</sup>Converted from efficacy to study-defined inefficacy by the authors.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In 2009 Barbui et al. analyzed all RCTs (irrespective of blindness and not necessarily placebo-controlled) between 1966 and 2007 on efficacy of clozapine in combination with a second antipsychotic versus clozapine monotherapy in schizophrenic patients partially responsive to clozapine (<xref ref-type="bibr" rid="bibr6-0269881113477709">Barbui et al., 2009</xref>). They included 21 randomized studies (six double blind placebo-controlled and 15 open RCTs) with a total of 1480 patients. Fifteen randomized trials were conducted in China, where diagnostic inclusion criteria were not based on Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria. Efficacy was defined as change in group mean score on a rating scale and proportion of patients without response. Open studies significantly favored combination strategies, while double blind studies did not. They concluded that the evidence base supporting clozapine combination strategies is weak, with modest to absent clinical benefit.</p>
<p>In the same year, a Cochrane systematic review was performed by Correll et al. (19 RCTs, including several studies in Chinese; 1216 patients) of studies combining a FGA and a SGA (including clozapine) in not necessarily treatment resistant schizophrenia (<xref ref-type="bibr" rid="bibr20-0269881113477709">Correll et al., 2009</xref>). The primary outcome was 50% symptom reduction on the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS). They concluded that in certain clinical situations antipsychotic co-treatment might be superior to monotherapy. However, the database was subject to possible publication bias favoring combinations and too heterogeneous to derive firm clinical recommendations.</p>
<p>In 2007 Paton et al. conducted a meta-analysis of RCTs investigating clozapine augmentation with another antipsychotic drug in patients partially responding to clozapine (<xref ref-type="bibr" rid="bibr66-0269881113477709">Paton et al., 2007</xref>). They included four studies with a total of 166 patients. Response was defined as a reduction of 20% or more on BPRS/PANSS total scores, although the clinical relevance of such a reduction is modest. Analysis by study duration (&gt;10 weeks) of RCTs accounted for heterogeneity in effect size, whereas analysis by drug did not. They concluded that in patients partially responsive to an adequate clozapine trial, augmentation with another antipsychotic drug in an individual clinical trial longer than six weeks might be useful.</p>
<p>Taylor and Smith performed an update of this study in 2009 with both new and unpublished trials, analyzing 10 randomized placebo-controlled trials of at least six weeks augmenting clozapine with a second antipsychotic (<xref ref-type="bibr" rid="bibr82-0269881113477709">Taylor and Smith, 2009</xref>). They found only weak evidence of therapeutic benefit with limited clinical significance and an association with study duration was not confirmed.</p>
<p>In 2012, Taylor et al. updated their 2009 meta-analysis of augmentation of clozapine with a second antipsychotic (<xref ref-type="bibr" rid="bibr83-0269881113477709">Taylor et al., 2012</xref>). They found four new RCTs, resulting in 14 RCTs (all placebo-controlled) including 734 patients. They concluded that augmentation of clozapine with a second antipsychotic is modestly beneficial and again no significant positive effect of treatment duration longer than 10 weeks.</p>
<p>A Cochrane systematic review published in 2010 by Wang et al. studied the additive effect of sulpiride augmentation to any antipsychotic (including clozapine) for people with schizophrenia or schizophrenia-like psychosis (<xref ref-type="bibr" rid="bibr87-0269881113477709">Wang et al., 2010</xref>). They identified four RCTs (three 8–12 weeks follow up, one with three years follow up) including 221 patients. Three of these RCTs were included in the earlier mentioned and broader review of Barbui et al. (<xref ref-type="bibr" rid="bibr6-0269881113477709">Barbui et al., 2009</xref>). The authors concluded that short-term (12 weeks) sulpiride plus clozapine is probably more effective than clozapine alone in producing clinical improvement in an unspecified subgroup of treatment resistant patients. However, the evidence was weak and prone to considerable publication bias in favor of positive studies.</p>
</sec>
<sec id="section14-0269881113477709">
<title>Tolerability</title>
<p>In studies investigating tolerability of APP, associations with several adverse drug effects were found.</p>
<sec id="section15-0269881113477709">
<title>High-dosing and extrapyramidal side effects</title>
<p>We found no systematic reviews investigating a possible association of APP with high-dosing or extrapyramidal side effects. In several cohort studies APP is associated with high-dose antipsychotic drug prescribing, in both inpatients and outpatients (<xref ref-type="bibr" rid="bibr5-0269881113477709">Barbui et al., 2006</xref>; <xref ref-type="bibr" rid="bibr69-0269881113477709">Ranceva et al., 2010</xref>). In a case-control study of APP, high dosing is associated with increased risk on extrapyramidal side effects (<xref ref-type="bibr" rid="bibr9-0269881113477709">Centorrino et al., 2004</xref>). In another case-control study, no difference in use of anticholinergics between monotherapy and polypharmacy groups was found, but this publication provides no information on prescribed doses (<xref ref-type="bibr" rid="bibr33-0269881113477709">Ganesan et al., 2008</xref>). High dosing might also be associated with acceleration of frontal gray matter reduction (<xref ref-type="bibr" rid="bibr90-0269881113477709">Weinmann and Aderhold, 2010</xref>).</p>
</sec>
<sec id="section16-0269881113477709">
<title>Increased mortality</title>
<p>We found one systematic review investigating the influence of antipsychotics on mortality in schizophrenia (<xref ref-type="bibr" rid="bibr92-0269881113477709">Weinmann et al., 2009</xref>). This review included 12 cohort studies comparing mortality in people with schizophrenia on antipsychotic medication versus people that did not use antipsychotics, not only on APP (<italic>n</italic>=4) but also on various doses of antipsychotic monotherapy (<italic>n</italic>=8). Due to several methodological problems, they could not conduct statistical analyses necessary for a meta-analysis. The included four uncontrolled cohort studies on APP were inconclusive. In a large, 11-year follow-up study including 66,881 patients with schizophrenia, published in the same year, overall mortality in patients on APP was no higher than in patients on antipsychotic monotherapy (<xref ref-type="bibr" rid="bibr85-0269881113477709">Tiihonen et al., 2009</xref>).</p>
</sec>
<sec id="section17-0269881113477709">
<title>Metabolic syndrome</title>
<p>We found no systematic reviews studying the risk of APP on the development of metabolic syndrome. In a large Danish study with 10-year follow-up the rates of incident diabetes significantly increased with the number of combined antipsychotic drugs from 1.48 (95% confidence interval (CI) 1.44–1.51) in patients prescribed one antipsychotic, 1.68 (95% CI 1.61–1.76) in the case of two concomitant antipsychotics, and up to 3.41 (95% CI 3.03–3.83) in patients on five or more antipsychotics (<xref ref-type="bibr" rid="bibr46-0269881113477709">Kessing et al., 2010</xref>). In a cross-sectional study, patients on APP have higher rates of metabolic syndrome and lipid markers of insulin resistance, but APP was not independently associated with these abnormalities but rather was postulated to potentiate underlying risk factors (<xref ref-type="bibr" rid="bibr19-0269881113477709">Correll et al., 2007</xref>). An association of APP with pre-metabolic syndrome (visceral fat obesity in combination with elevated blood glucose, lipid abnormalities or elevated blood pressure) was found even after correcting for patients’ lifestyle characteristics but not with metabolic syndrome (<xref ref-type="bibr" rid="bibr58-0269881113477709">Misawa et al., 2011</xref>). These findings suggest that APP is perhaps a mediating, rather than a direct, factor for metabolic syndrome but nevertheless might contribute to increased cardiovascular morbidity.</p>
</sec>
<sec id="section18-0269881113477709">
<title>Cognitive dysfunction</title>
<p>We found no systematic reviews investigating APP in relation to cognitive dysfunction. In two cross-sectional studies, APP is associated with decreased cognitive functioning (<xref ref-type="bibr" rid="bibr11-0269881113477709">Chakos et al., 2006</xref>; <xref ref-type="bibr" rid="bibr39-0269881113477709">Hori et al., 2006</xref>). This is probably due to excessive antipsychotic dosage and cumulative anticholinergic activity rather than number of antipsychotic drugs (<xref ref-type="bibr" rid="bibr25-0269881113477709">Elie et al., 2010</xref>). A third study, however, found no association between APP or high-dosing and non-verbal cognitive functioning (<xref ref-type="bibr" rid="bibr47-0269881113477709">Kontis et al., 2010</xref>).</p>
</sec>
<sec id="section19-0269881113477709">
<title>Non-adherence</title>
<p>Complexity of medication regime is associated with non-adherence (<xref ref-type="bibr" rid="bibr13-0269881113477709">Chen, 1991</xref>), suggesting that APP might increase the risk of non-adherence (<xref ref-type="bibr" rid="bibr70-0269881113477709">Schorr et al., 2008</xref>). However, we did not find any clinical studies in patients receiving APP confirming this hypothesis.</p>
</sec>
</sec>
<sec id="section20-0269881113477709">
<title>Cost-effectiveness</title>
<p>We found no systematic reviews or controlled trials investigating cost-effectiveness of APP. A large (pharmaceutical industry funded) nonrandomized naturalistic prospective study concludes that APP adds substantial cost to treatment of schizophrenia (<xref ref-type="bibr" rid="bibr101-0269881113477709">Zhu et al., 2008</xref>). These costs may be up to three times more per patient compared to monotherapy in the case of combination of two SGAs (<xref ref-type="bibr" rid="bibr78-0269881113477709">Stahl and Grady, 2006</xref>). In a cross-sectional observational study, APP is also associated with increased use of health care services (<xref ref-type="bibr" rid="bibr4-0269881113477709">Baandrup et al., 2012</xref>). There is no evidence that these extra costs would be compensated by the reduction of other health care costs resulting from higher level of social functioning, less hospitalization or reduced duration of hospitalization (<xref ref-type="bibr" rid="bibr9-0269881113477709">Centorrino et al., 2004</xref>; <xref ref-type="bibr" rid="bibr18-0269881113477709">Clark et al., 2002</xref>; <xref ref-type="bibr" rid="bibr42-0269881113477709">Janssen et al., 2004</xref>; <xref ref-type="bibr" rid="bibr78-0269881113477709">Stahl and Grady, 2006</xref>).</p>
</sec>
</sec>
<sec id="section21-0269881113477709" sec-type="discussion">
<title>Discussion</title>
<p>The translational research model as proposed by Honer et al. (<xref ref-type="bibr" rid="bibr37-0269881113477709">Honer et al., 2009</xref>) stresses the importance of including basic science, knowledge on efficacy, tolerability as well as cost-effectiveness in the process of improving high-quality pharmacotherapy for patients with schizophrenia. It also provides a model that reveals gaps that need to be addressed before practicing APP as a high-quality pharmacotherapeutic strategy in psychotic disorders.</p>
<p>Our literature study reveals that APP is often based on neurobiological hypotheses that have minimal attention in pre-clinical or clinical research and lack empirical evidence. The dopamine hypothesis is the most investigated theoretical framework for APP. However it is insufficient, especially in non-clozapine combinations, since both antipsychotic agents compete with the same D<sub>2</sub>-receptor. In addition in APP involving clozapine the concept is insufficient since the antipsychotic with the weakest D<sub>2</sub> binding (clozapine) is replaced by the added antipsychotic that has stronger D<sub>2</sub> affinity (<xref ref-type="bibr" rid="bibr82-0269881113477709">Taylor and Smith, 2009</xref>).</p>
<p>Efficacy of APP is limited to some evidence in augmenting patients (partially) resistant to clozapine, however with modest clinical benefit. Positive results are associated more with treatment duration of 10 or more weeks than with the added antipsychotic agent, especially in clozapine-treated patients. However, partially due to the complexity of the subject and the investigated population, studies are hampered by low patient numbers, large variety in duration of illness, mixing patients that received clozapine treatment and patients that did not, unclear criteria in case of refractoriness, lack of adequate control for confounders (e.g. in time cumulating antipsychotic effect or pharmacokinetic interactions resulting in altered blood levels of the primary agent), short follow up periods, frequent absence of assessment scales evaluating effect and risk of publication bias, limiting definitive conclusions (<xref ref-type="bibr" rid="bibr79-0269881113477709">Stern et al., 1997</xref>; <xref ref-type="bibr" rid="bibr86-0269881113477709">Tranulis et al., 2008</xref>).</p>
<p>APP is associated with several serious risks such as high dosing, increased mortality, metabolic syndrome, cognitive impairment and non-adherence: however, causality has not been demonstrated. Except for non-adherence, these adverse effects may as well be related to excessive dosing (or severity of the psychotic disorder itself) as to the number of prescribed antipsychotics. APP increases medication cost without evidence supporting cost-effectiveness.</p>
<p>According to the currently available evidence, short-term APP can be appropriate in a process of switching antipsychotics that may last up to 70 days in the case of switching to some long- acting antipsychotics (see: <ext-link ext-link-type="uri" xlink:href="http://www.switchingantipsychotics.eu">www.switchingantipsychotics.eu</ext-link>). This switch needs to be completed, even if a patient recovers during the switch, in order to prevent getting trapped in cross-titration (<xref ref-type="bibr" rid="bibr76-0269881113477709">Stahl, 1999</xref>). APP can also be appropriate as a trial in patients with severe psychotic symptoms not responding to adequate trials of successively two different antipsychotics and clozapine. These findings are in line with current recommendations in clinical guidelines (<xref ref-type="bibr" rid="bibr1-0269881113477709">American Psychiatric Association, 2004</xref>; <xref ref-type="bibr" rid="bibr62-0269881113477709">National Institute for Clinical Excellence, 2009</xref>).</p>
<p>Reducing persistent APP to monotherapy without clinical deterioration has been successfully demonstrated in both inpatient and outpatient studies, although some patients relapsed (<xref ref-type="bibr" rid="bibr15-0269881113477709">Chong et al., 2006</xref>; <xref ref-type="bibr" rid="bibr26-0269881113477709">Essock et al., 2011</xref>; <xref ref-type="bibr" rid="bibr80-0269881113477709">Suzuki et al., 2004</xref>). There is some evidence that intensive auditing and feedback from pharmacists may be effective in reducing inappropriate APP (<xref ref-type="bibr" rid="bibr35-0269881113477709">Hazra et al., 2011</xref>; <xref ref-type="bibr" rid="bibr91-0269881113477709">Weinmann et al., 2008</xref>), although clinicians’ prescribing practices do not change easily (<xref ref-type="bibr" rid="bibr40-0269881113477709">Howes et al., 2012</xref>). There are indications that persistent APP in inpatients might be a valid indicator to identify treatment problems and provides opportunities to enhance quality of treatment (<xref ref-type="bibr" rid="bibr42-0269881113477709">Janssen et al., 2004</xref>).</p>
<p>A limitation is the small number of methodologically heterogeneous studies addressing antipsychotic polypharmacy that are included in the six reviews. Only one of these six reviews included non-clozapine combinations (<xref ref-type="bibr" rid="bibr20-0269881113477709">Correll et al., 2009</xref>). More research is needed in the prevention of inappropriate persistent APP (including high-dosing) by addressing beliefs and attitudes of clinicians towards APP (<xref ref-type="bibr" rid="bibr21-0269881113477709">Correll et al., 2011</xref>). There also is an urgent need for more evidence-based guidance (e.g. more effective therapeutics) in patients with clozapine refractory psychotic symptoms that account for 25–30% or even more of patients suffering from schizophrenia and in which several somatic and pharmacotherapeutic strategies (including persistent APP) are frequently practiced by trial and error. We need to understand more about the characteristics of the subgroup of psychotic patients that appear to benefit from APP (including non-clozapine combinations) and relapses when revised to monotherapy versus the subgroup that does not relapse. Such research needs large double blind controlled trials with independent financial funding. However, RCTs may not be the most appropriate approach to address these issues because of the methodological problems mentioned above and limitations in external validity to real world clinical practice (<xref ref-type="bibr" rid="bibr77-0269881113477709">Stahl, 2012</xref>). Naturalistic prospective study designs as well can provide opportunities to include larger numbers of patients and compare outcomes of different combination strategies (<xref ref-type="bibr" rid="bibr57-0269881113477709">Miller and Craig, 2002</xref>). Routine outcome monitoring (ROM) can be a useful supportive tool to monitor systematically and thoroughly clinical and functional outcome in these studies.</p>
<p>Meanwhile, because of potential serious risks and modest clinical benefits, APP should be practiced with great caution (<xref ref-type="bibr" rid="bibr50-0269881113477709">Langan and Shajahan, 2010</xref>). In clozapine refractory patients a trial with APP of sufficient duration (at least 10 weeks) with well-defined evaluation criteria (with use of rating scales integrated in ROM) can be a modest option that needs to be weighted against benefits and risks of other biological interventions in treatment resistant psychosis. If this trial proves ineffective, advice is to return to monotherapy with the primary agent.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflicts of interest</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881113477709">
<citation citation-type="journal">
<collab>American Psychiatric Association</collab>. (<year>2004</year>) <article-title>Practice guideline for the treatment of patients with schizophrenia, second edition</article-title>. <source>Am J Psychiatry</source> <volume>161</volume>: <fpage>1</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr2-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anil Yagcioglu</surname><given-names>AE</given-names></name>
<name><surname>Kivircik Akdede</surname><given-names>BB</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety</article-title>. <source>J Clin Psychiatry</source> <volume>66</volume>: <fpage>63</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr3-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Assion</surname><given-names>HJ</given-names></name>
<name><surname>Reinbold</surname><given-names>H</given-names></name>
<name><surname>Lemanski</surname><given-names>S</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial</article-title>. <source>Pharmacopsychiatry</source> <volume>41</volume>: <fpage>24</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr4-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baandrup</surname><given-names>L</given-names></name>
<name><surname>Sorensen</surname><given-names>J</given-names></name>
<name><surname>Lublin</surname><given-names>H</given-names></name><etal/>
</person-group> (<year>2012</year>) <article-title>Association of antipsychotic polypharmacy with health service cost: A register-based cost analysis</article-title>. <source>Eur J Health Econ</source> <volume>13</volume>: <fpage>355</fpage>–<lpage>363</lpage>.</citation>
</ref>
<ref id="bibr5-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbui</surname><given-names>C</given-names></name>
<name><surname>Nosè</surname><given-names>M</given-names></name>
<name><surname>Mazzi</surname><given-names>MA</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries</article-title>. <source>Int Clin Psychopharmacol</source> <volume>21</volume>: <fpage>355</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr6-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbui</surname><given-names>C</given-names></name>
<name><surname>Signoretti</surname><given-names>A</given-names></name>
<name><surname>Mulè</surname><given-names>S</given-names></name><etal/>
</person-group> (<year>2009</year>) <article-title>Does the addition of a second antipsychotic drug improve clozapine treatment?</article-title> <source>Schizophr Bull</source> <volume>35</volume>: <fpage>458</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr7-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrett</surname><given-names>WW</given-names></name>
<name><surname>Ellsworth</surname><given-names>RB</given-names></name>
<name><surname>Clark</surname><given-names>LD</given-names></name><etal/>
</person-group> (<year>1957</year>) <article-title>Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients</article-title>. <source>Dis Nerv Syst</source> <volume>18</volume>: <fpage>209</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr8-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broekema</surname><given-names>WJ</given-names></name>
<name><surname>de Groot</surname><given-names>IW</given-names></name>
<name><surname>van Harten</surname><given-names>PN</given-names></name>
</person-group> (<year>2007</year>) <article-title>Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - a European study</article-title>. <source>Pharm World Sci</source> <volume>29</volume>: <fpage>126</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr9-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Centorrino</surname><given-names>F</given-names></name>
<name><surname>Goren</surname><given-names>JL</given-names></name>
<name><surname>Hennen</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case- control study of risks versus benefits</article-title>. <source>Am J Psychiatry</source> <volume>161</volume>: <fpage>700</fpage>–<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr10-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cha</surname><given-names>C</given-names></name>
<name><surname>Hui</surname><given-names>G</given-names></name>
<name><surname>Quing</surname><given-names>G</given-names></name>
</person-group> (<year>1999</year>) <article-title>Evaluation of therapeutic effect with chlorpromazine and clozapine for the treatment of schizophrenia</article-title>. <source>Xinxiang Med Stud</source> <volume>16</volume>: <fpage>311</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr11-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chakos</surname><given-names>MH</given-names></name>
<name><surname>Glick</surname><given-names>ID</given-names></name>
<name><surname>Miller</surname><given-names>AL</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial</article-title>. <source>Psychiatr Serv</source> <volume>57</volume>: <fpage>1094</fpage>–<lpage>1101</lpage>.</citation>
</ref>
<ref id="bibr12-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>JS</given-names></name>
<name><surname>Ahn</surname><given-names>YM</given-names></name>
<name><surname>Park</surname><given-names>HJ</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial</article-title>. <source>J Clin Psychiatry</source> <volume>69</volume>: <fpage>720</fpage>–<lpage>731</lpage>.</citation>
</ref>
<ref id="bibr13-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>A</given-names></name>
</person-group> (<year>1991</year>) <article-title>Noncompliance in community psychiatry: A review of clinical interventions</article-title>. <source>Hosp Community Psychiatry</source> <volume>42</volume>: <fpage>282</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr14-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chien</surname><given-names>CP</given-names></name>
<name><surname>Cole</surname><given-names>JO</given-names></name>
</person-group> (<year>1973</year>) <article-title>Depot phenothiazine treatment in acute psychosis: A sequential comparative clinical study</article-title>. <source>Am J Psychiatry</source> <volume>130</volume>: <fpage>13</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr15-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chong</surname><given-names>SA</given-names></name>
<name><surname>Ravichandran</surname><given-names>N</given-names></name>
<name><surname>Poon</surname><given-names>LY</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Reducing polypharmacy through the introduction of a treatment algorithm: Use of a treatment algorithm on the impact on polypharmacy</article-title>. <source>Ann Acad Med Singapore</source> <volume>35</volume>: <fpage>457</fpage>–<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr16-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chong</surname><given-names>SA</given-names></name>
<name><surname>Remington</surname><given-names>GJ</given-names></name>
</person-group> (<year>2000</year>) <article-title>Clozapine augmentation: Safety and efficacy</article-title>. <source>Schizophr Bull</source> <volume>26</volume>: <fpage>421</fpage>–<lpage>440</lpage>.</citation>
</ref>
<ref id="bibr17-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Boso</surname><given-names>M.</given-names></name>
<name><surname>Barbui</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia</article-title>. <source>Cochrane Database Syst Rev</source>. <fpage>CD006324</fpage>.</citation>
</ref>
<ref id="bibr18-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clark</surname><given-names>RE</given-names></name>
<name><surname>Bartels</surname><given-names>SJ</given-names></name>
<name><surname>Mellman</surname><given-names>TA</given-names></name><etal/>
</person-group> (<year>2002</year>) <article-title>Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy</article-title>. <source>Schizophr Bull</source> <volume>28</volume>: <fpage>75</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr19-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correll</surname><given-names>CU</given-names></name>
<name><surname>Frederickson</surname><given-names>AM</given-names></name>
<name><surname>Kane</surname><given-names>JM</given-names></name><etal/>
</person-group> (<year>2007</year>) <article-title>Does antipsychotic polypharmacy increase the risk for metabolic syndrome?</article-title> <source>Schizophr Res</source> <volume>89</volume>: <fpage>91</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr20-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correll</surname><given-names>CU</given-names></name>
<name><surname>Rummel-Kluge</surname><given-names>C</given-names></name>
<name><surname>Corves</surname><given-names>C</given-names></name><etal/>
</person-group> (<year>2009</year>) <article-title>Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials</article-title>. <source>Schizophr Bull</source> <volume>35</volume>: <fpage>443</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr21-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correll</surname><given-names>CU</given-names></name>
<name><surname>Shaikh</surname><given-names>L</given-names></name>
<name><surname>Gallego</surname><given-names>JA</given-names></name><etal/>
</person-group> (<year>2011</year>) <article-title>Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior</article-title>. <source>Schizophr Res</source> <volume>131</volume>: <fpage>58</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr22-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Di Pietro</surname><given-names>NC</given-names></name>
<name><surname>Seamans</surname><given-names>JK</given-names></name>
</person-group> (<year>2007</year>) <article-title>Dopamine and serotonin interactions in the prefrontal cortex: Insights on antipsychotic drugs and their mechanism of action</article-title>. <source>Pharmacopsychiatry</source> <volume>40</volume>: <fpage>S27</fpage>–<lpage>S33</lpage>.</citation>
</ref>
<ref id="bibr23-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dougherty</surname><given-names>D</given-names></name>
<name><surname>Conway</surname><given-names>PH</given-names></name>
</person-group> (<year>2008</year>) <article-title>The ‘3T’s’ road map to transform US health care</article-title>. <source>JAMA</source> <volume>299</volume>: <fpage>2319</fpage>–<lpage>2321</lpage>.</citation>
</ref>
<ref id="bibr24-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Egbe</surname><given-names>P</given-names></name>
<name><surname>Engel</surname><given-names>J</given-names></name>
<name><surname>Gustafsson</surname><given-names>B</given-names></name><etal/>
</person-group> (<year>1990</year>) <article-title>Amperozide and conditioned behaviour in rats: Potentiation by classical neuroleptics and alpha-methylparatyrosine</article-title>. <source>Pharmacol Toxicol</source> <volume>66</volume>: <fpage>18</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr25-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elie</surname><given-names>D</given-names></name>
<name><surname>Poirier</surname><given-names>M</given-names></name>
<name><surname>Chianetta</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder</article-title>. <source>J Psychopharmacol</source> <volume>24</volume>: <fpage>1037</fpage>–<lpage>1044</lpage>.</citation>
</ref>
<ref id="bibr26-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Essock</surname><given-names>SM</given-names></name>
<name><surname>Schooler</surname><given-names>NR</given-names></name>
<name><surname>Stroup</surname><given-names>TS</given-names></name><etal/>
</person-group> (<year>2011</year>) <article-title>Effectiveness of switching from antipsychotic polypharmacy to monotherapy</article-title>. <source>Am J Psychiatry</source> <volume>168</volume>: <fpage>702</fpage>–<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr27-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleischhacker</surname><given-names>W</given-names></name>
<name><surname>Heikkinen</surname><given-names>ME</given-names></name>
<name><surname>Olié</surname><given-names>JP</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study</article-title>. <source>Eur Psychiatry</source> <volume>23</volume>: <fpage>S114</fpage>–<lpage>S115</lpage>.</citation>
</ref>
<ref id="bibr28-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleischhacker</surname><given-names>WW</given-names></name>
<name><surname>Heikkinen</surname><given-names>ME</given-names></name>
<name><surname>Olie</surname><given-names>JP</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>13</volume>: <fpage>1115</fpage>–<lpage>1125</lpage>.</citation>
</ref>
<ref id="bibr29-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freudenreich</surname><given-names>O</given-names></name>
<name><surname>Goff</surname><given-names>DC</given-names></name>
</person-group> (<year>2002</year>) <article-title>Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations</article-title>. <source>Acta Psychiatr Scand</source> <volume>106</volume>: <fpage>323</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr30-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freudenreich</surname><given-names>O</given-names></name>
<name><surname>Henderson</surname><given-names>DC</given-names></name>
<name><surname>Walsh</surname><given-names>JP</given-names></name><etal/>
</person-group> (<year>2007</year>) <article-title>Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial</article-title>. <source>Schizophr Res</source> <volume>92</volume>: <fpage>90</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr31-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>JI</given-names></name>
<name><surname>Lindenmayer</surname><given-names>JP</given-names></name>
<name><surname>Alcantara</surname><given-names>F</given-names></name><etal/>
</person-group> (<year>2011</year>) <article-title>Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy</article-title>. <source>Neuropsychopharmacology</source> <volume>36</volume>: <fpage>1289</fpage>–<lpage>1295</lpage>.</citation>
</ref>
<ref id="bibr32-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallego</surname><given-names>JA</given-names></name>
<name><surname>Bonetti</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2012</year>) <article-title>Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009</article-title>. <source>Schizophr Res</source> <volume>138</volume>: <fpage>18</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr33-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ganesan</surname><given-names>S</given-names></name>
<name><surname>Taylor</surname><given-names>R</given-names></name>
<name><surname>Forbes</surname><given-names>I</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Antipsychotic polypharmacy does not increase the risk for side effects</article-title>. <source>Schizophr Res</source> <volume>98</volume>: <fpage>323</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr34-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Genc</surname><given-names>Y</given-names></name>
<name><surname>Taner</surname><given-names>E.</given-names></name>
<name><surname>Candansayar</surname><given-names>S</given-names></name>
</person-group> (<year>2007</year>) <article-title>Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study</article-title>. <source>Adv Ther</source> <volume>24</volume>: <fpage>1</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr35-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hazra</surname><given-names>M</given-names></name>
<name><surname>Uchida</surname><given-names>H</given-names></name>
<name><surname>Sproule</surname><given-names>B</given-names></name><etal/>
</person-group> (<year>2011</year>) <article-title>Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia</article-title>. <source>Psychiatry Clin Neurosci</source> <volume>65</volume>: <fpage>676</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr36-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higashima</surname><given-names>M</given-names></name>
<name><surname>Takeda</surname><given-names>T</given-names></name>
<name><surname>Nagasawa</surname><given-names>T</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia</article-title>. <source>Eur Psychiatry</source> <volume>19</volume>: <fpage>380</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr37-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Honer</surname><given-names>WG</given-names></name>
<name><surname>Procyshyn</surname><given-names>RM</given-names></name>
<name><surname>Chen</surname><given-names>EY</given-names></name><etal/>
</person-group> (<year>2009</year>) <article-title>A translational research approach to poor treatment response in patients with schizophrenia: Clozapine-antipsychotic polypharmacy</article-title>. <source>J Psychiatry Neurosci</source> <volume>34</volume>: <fpage>433</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr38-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Honer</surname><given-names>WG</given-names></name>
<name><surname>Thornton</surname><given-names>AE</given-names></name>
<name><surname>Chen</surname><given-names>EY</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Clozapine alone versus clozapine and risperidone with refractory schizophrenia</article-title>. <source>N Engl J Med</source> <volume>354</volume>: <fpage>472</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr39-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hori</surname><given-names>H</given-names></name>
<name><surname>Noguchi</surname><given-names>H</given-names></name>
<name><surname>Hashimoto</surname><given-names>R</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Antipsychotic medication and cognitive function in schizophrenia</article-title>. <source>Schizophr Res</source> <volume>86</volume>: <fpage>138</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr40-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howes</surname><given-names>OD</given-names></name>
<name><surname>Vergunst</surname><given-names>F</given-names></name>
<name><surname>Gee</surname><given-names>S</given-names></name><etal/>
</person-group> (<year>2012</year>) <article-title>Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation</article-title>. <source>Br J Psychiatry</source> <volume>201</volume>: <fpage>481</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr41-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ito</surname><given-names>H</given-names></name>
<name><surname>Koyama</surname><given-names>A</given-names></name>
<name><surname>Higuchi</surname><given-names>T</given-names></name>
</person-group> (<year>2005</year>) <article-title>Polypharmacy and excessive dosing: Psychiatrists’ perceptions of antipsychotic drug prescription</article-title>. <source>Br J Psychiatry</source> <volume>187</volume>: <fpage>243</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr42-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Janssen</surname><given-names>B</given-names></name>
<name><surname>Weinmann</surname><given-names>S</given-names></name>
<name><surname>Berger</surname><given-names>M</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Validation of polypharmacy process measures in inpatient schizophrenia care</article-title>. <source>Schizophr Bull</source> <volume>30</volume>: <fpage>1023</fpage>–<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr43-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jia</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Jin</surname><given-names>S</given-names></name>
</person-group> (<year>2000</year>) <article-title>A controlled trial for comparing clozapine combined with pipothiazine palmitate to clozapine alone in the treatment of negative symptoms in schizophrenic patients</article-title>. <source>Herald Med</source> <volume>19</volume>: <fpage>142</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr44-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Josiassen</surname><given-names>RC</given-names></name>
<name><surname>Joseph</surname><given-names>A</given-names></name>
<name><surname>Kohegyi</surname><given-names>E</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial</article-title>. <source>Am J Psychiatry</source> <volume>162</volume>: <fpage>130</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr45-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kapur</surname><given-names>S</given-names></name>
<name><surname>Roy</surname><given-names>P</given-names></name>
<name><surname>Daskalakis</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2001</year>) <article-title>Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine</article-title>. <source>Am J Psychiatry</source> <volume>158</volume>: <fpage>311</fpage>–<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr46-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessing</surname><given-names>LV</given-names></name>
<name><surname>Thomsen</surname><given-names>AF</given-names></name>
<name><surname>Mogensen</surname><given-names>UB</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Treatment with antipsychotics and the risk of diabetes in clinical practice</article-title>. <source>Br J Psychiatry</source> <volume>197</volume>: <fpage>266</fpage>–<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr47-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kontis</surname><given-names>D</given-names></name>
<name><surname>Theochari</surname><given-names>E</given-names></name>
<name><surname>Kleisas</surname><given-names>S</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>34</volume>: <fpage>1333</fpage>–<lpage>1341</lpage>.</citation>
</ref>
<ref id="bibr48-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kotler</surname><given-names>M</given-names></name>
<name><surname>Strous</surname><given-names>RD</given-names></name>
<name><surname>Reznik</surname><given-names>I</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology</article-title>. <source>Int Clin Psychopharmacol</source> <volume>19</volume>: <fpage>23</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr49-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreinin</surname><given-names>A</given-names></name>
<name><surname>Novitski</surname><given-names>D</given-names></name>
<name><surname>Weizman</surname><given-names>A</given-names></name>
</person-group> (<year>2006</year>) <article-title>Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study</article-title>. <source>Int Clin Psychopharmacol</source> <volume>21</volume>: <fpage>99</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr50-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langan</surname><given-names>J</given-names></name>
<name><surname>Shajahan</surname><given-names>P</given-names></name>
</person-group> (<year>2010</year>) <article-title>Antipsychotic polypharmacy: Review of mechanisms, mortality and management</article-title>. <source>Psychiatrist</source> <volume>34</volume>: <fpage>58</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr51-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
</person-group> (<year>2001</year>) <article-title>A comparative study on the efficacy of combining risperidone and clozapine in the treatment of schizophrenia</article-title>. <source>Shandon Arch Psychiatry</source> <volume>14</volume>: <fpage>28</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr52-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
</person-group> (<year>1996</year>) <article-title>A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia</article-title>. <source>Chin J Psychiatry</source> <volume>29</volume>: <fpage>87</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr53-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matthiasson</surname><given-names>P</given-names></name>
<name><surname>Erlandsson</surname><given-names>K</given-names></name>
<name><surname>Costa</surname><given-names>DC</given-names></name><etal/>
</person-group> (<year>2003</year>) <article-title>Amisulpride augmentation of clozapine and striatal dopamine D2 receptor binding potential. A 123-I IBZM SPET study</article-title>. <source>Schizophr Res</source> <volume>53</volume>: <fpage>208</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr54-0269881113477709">
<citation citation-type="book"><collab>Medical Directors Council and State Medicaid Directors</collab>. (<year>2001</year>) <source>Technical Report on Psychiatric Polypharmacy</source>. <publisher-name>National Association of State Mental Health Program Directors (NASMHPD)</publisher-name>, <day>9</day> <month>October</month>. <publisher-loc>Alexandria, Virginia</publisher-loc>.</citation>
</ref>
<ref id="bibr55-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meltzer</surname><given-names>HY</given-names></name>
<name><surname>Matsubara</surname><given-names>S</given-names></name>
<name><surname>Lee</surname><given-names>JC</given-names></name>
</person-group> (<year>1989</year>) <article-title>The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs</article-title>. <source>Psychopharmacol Bull</source> <volume>25</volume>: <fpage>390</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr56-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meltzer</surname><given-names>HY</given-names></name>
<name><surname>Stahl</surname><given-names>SM</given-names></name>
</person-group> (<year>1976</year>) <article-title>The dopamine hypothesis of schizophrenia: A review</article-title>. <source>Schizophr Bull</source> <volume>2</volume>: <fpage>19</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr57-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>AL</given-names></name>
<name><surname>Craig</surname><given-names>CS</given-names></name>
</person-group> (<year>2002</year>) <article-title>Combination antipsychotics: Pros, cons, and questions</article-title>. <source>Schizophr Bull</source> <volume>28</volume>: <fpage>105</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr58-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Misawa</surname><given-names>F</given-names></name>
<name><surname>Shimizu</surname><given-names>K</given-names></name>
<name><surname>Fujii</surname><given-names>Y</given-names></name><etal/>
</person-group> (<year>2011</year>) <article-title>Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study</article-title>. <source>BMC Psychiatry</source> <volume>11</volume>: <fpage>118</fpage>.</citation>
</ref>
<ref id="bibr59-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>TA</given-names></name>
<name><surname>Buchanan</surname><given-names>RW</given-names></name>
<name><surname>Buckley</surname><given-names>PF</given-names></name><etal/>
</person-group> (<year>2007</year>) <article-title>The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update</article-title>. <source>J Clin Psychiatry</source> <volume>68</volume>: <fpage>1751</fpage>–<lpage>1762</lpage>.</citation>
</ref>
<ref id="bibr60-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mossaheb</surname><given-names>N</given-names></name>
<name><surname>Sacher</surname><given-names>J</given-names></name>
<name><surname>Wiesegger</surname><given-names>G</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>4</volume>: <fpage>S416</fpage>.</citation>
</ref>
<ref id="bibr61-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muscatello</surname><given-names>MR</given-names></name>
<name><surname>Bruno</surname><given-names>A</given-names></name>
<name><surname>Pandolfo</surname><given-names>G</given-names></name><etal/>
</person-group> (<year>2011</year>) <article-title>Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study</article-title>. <source>Schizophr Res</source> <volume>127</volume>: <fpage>93</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr62-0269881113477709">
<citation citation-type="book"><collab>National Institute for Clinical Excellence</collab>. (<year>2009</year>) <source>Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care</source> (<edition>updated edition</edition>). <publisher-loc>London</publisher-loc>: <publisher-name>The British Psychological Society &amp; The Royal College of Psychiatrists</publisher-name>.</citation>
</ref>
<ref id="bibr63-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ni</surname><given-names>J</given-names></name>
<name><surname>Jang</surname><given-names>L</given-names></name>
<name><surname>Hong</surname><given-names>X</given-names></name>
</person-group> (<year>2001</year>) <article-title>Therapeutic effects of clozapine, risperidone and their combination in the treatment of schizophrenia</article-title>. <source>Heath Psychol J</source> <volume>3</volume>: <fpage>181</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr64-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>J</given-names></name>
<name><surname>Emborg</surname><given-names>C</given-names></name>
<name><surname>Gydesen</surname><given-names>S</given-names></name><etal/>
</person-group> (<year>2012</year>) <article-title>Augmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study</article-title>. <source>J Clin Psychopharmacol</source> <volume>32</volume>: <fpage>173</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr65-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishikawa</surname><given-names>T</given-names></name>
<name><surname>Tsuda</surname><given-names>A</given-names></name>
<name><surname>Tanaka</surname><given-names>M</given-names></name><etal/>
</person-group> (<year>1985</year>) <article-title>Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers</article-title>. <source>Biol Psychiatry</source> <volume>20</volume>: <fpage>1161</fpage>–<lpage>1166</lpage>.</citation>
</ref>
<ref id="bibr66-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paton</surname><given-names>C</given-names></name>
<name><surname>Whittington</surname><given-names>C</given-names></name>
<name><surname>Barnes</surname><given-names>TR</given-names></name>
</person-group> (<year>2007</year>) <article-title>Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: A meta-analysis</article-title>. <source>J Clin Psychopharmacol</source> <volume>27</volume>: <fpage>198</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr67-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peng</surname><given-names>H</given-names></name>
<name><surname>Kuang</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
</person-group> (<year>2001</year>) <article-title>A control study of risperidone in combination with clozapine in treating refractory schizophrenia</article-title>. <source>J Mod Clin Med Bioeng</source> <volume>7</volume>: <fpage>100</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr68-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potter</surname><given-names>WZ</given-names></name>
<name><surname>Ko</surname><given-names>GN</given-names></name>
<name><surname>Zhang</surname><given-names>LD</given-names></name><etal/>
</person-group> (<year>1989</year>) <article-title>Clozapine in China: A review and preview of US/PRC collaboration</article-title>. <source>Psychopharmacology (Berl)</source> <volume>99</volume>: <fpage>S87</fpage>–<lpage>S91</lpage>.</citation>
</ref>
<ref id="bibr69-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ranceva</surname><given-names>N</given-names></name>
<name><surname>Ashraf</surname><given-names>W</given-names></name>
<name><surname>Odelola</surname><given-names>D</given-names></name>
</person-group> (<year>2010</year>) <article-title>Antipsychotic polypharmacy in outpatients at Birch Hill Hospital</article-title>. <source>J Clin Pharmacol</source> <volume>50</volume>: <fpage>699</fpage>–<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr70-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schorr</surname><given-names>SG</given-names></name>
<name><surname>Loonen</surname><given-names>AJ</given-names></name>
<name><surname>Brouwers</surname><given-names>JR</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>A cross-sectional study of prescribing patterns in chronic psychiatric patients living in sheltered housing facilities</article-title>. <source>Int J Clin Pharmacol Ther</source> <volume>46</volume>: <fpage>146</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr71-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seeman</surname><given-names>P</given-names></name>
<name><surname>Tallerico</surname><given-names>T</given-names></name>
</person-group> (<year>1998</year>) <article-title>Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors</article-title>. <source>Mol Psychiatry</source> <volume>3</volume>: <fpage>123</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr72-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sernyak</surname><given-names>MJ</given-names></name>
<name><surname>Rosenheck</surname><given-names>R</given-names></name>
</person-group> (<year>2004</year>) <article-title>Clinicians’ reasons for antipsychotic coprescribing</article-title>. <source>J Clin Psychiatry</source> <volume>65</volume>: <fpage>1597</fpage>–<lpage>1600</lpage>.</citation>
</ref>
<ref id="bibr73-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shiloh</surname><given-names>R</given-names></name>
<name><surname>Zemishlany</surname><given-names>Z</given-names></name>
<name><surname>Aizenberg</surname><given-names>D</given-names></name><etal/>
</person-group> (<year>1997</year>) <article-title>Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study</article-title>. <source>Br J Psychiatry</source> <volume>171</volume>: <fpage>569</fpage>–<lpage>573</lpage>.</citation>
</ref>
<ref id="bibr74-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shim</surname><given-names>JC</given-names></name>
<name><surname>Shin</surname><given-names>JG</given-names></name>
<name><surname>Kelly</surname><given-names>DL</given-names></name><etal/>
</person-group> (<year>2007</year>) <article-title>Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial</article-title>. <source>Am J Psychiatry</source> <volume>164</volume>: <fpage>1404</fpage>–<lpage>1410</lpage>.</citation>
</ref>
<ref id="bibr75-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Si</surname><given-names>S</given-names></name>
<name><surname>Yuan</surname><given-names>C</given-names></name>
</person-group> (<year>1999</year>) <article-title>A comparative trial of the effects of sulpiride combined with clozapine in the treatment of chronic schizophrenia</article-title>. <source>Shandon Arch Psychiatry</source> <volume>12</volume>: <fpage>17</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr76-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
</person-group> (<year>1999</year>) <article-title>Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?</article-title> <source>J Clin Psychiatry</source> <volume>60</volume>: <fpage>425</fpage>–<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr77-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
</person-group> (<year>2012</year>) <article-title>Antipsychotic polypharmacy: Never say never, but never say always</article-title>. <source>Acta Psychiatr Scand</source> <volume>125</volume>: <fpage>349</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr78-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
<name><surname>Grady</surname><given-names>MM</given-names></name>
</person-group> (<year>2006</year>) <article-title>High-cost use of second-generation antipsychotics under California’s Medicaid program</article-title>. <source>Psychiatr Serv</source> <volume>57</volume>: <fpage>127</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr79-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stern</surname><given-names>RG</given-names></name>
<name><surname>Schmeidler</surname><given-names>J</given-names></name>
<name><surname>Davidson</surname><given-names>M</given-names></name>
</person-group> (<year>1997</year>) <article-title>Limitations of controlled augmentation trials in schizophrenia</article-title>. <source>Biol Psychiatry</source> <volume>42</volume>: <fpage>138</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr80-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Uchida</surname><given-names>H</given-names></name>
<name><surname>Tanaka</surname><given-names>KF</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>7</volume>: <fpage>133</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr81-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Talbot</surname><given-names>DR</given-names></name>
</person-group> (<year>1964</year>) <article-title>Are tranquilizer combinations more effective than a single tranquilizer?</article-title> <source>Am J Psychiatry</source> <volume>121</volume>: <fpage>597</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr82-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>DM</given-names></name>
<name><surname>Smith</surname><given-names>L</given-names></name>
</person-group> (<year>2009</year>) <article-title>Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies</article-title>. <source>Acta Psychiatr Scand</source> <volume>119</volume>: <fpage>419</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr83-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>DM</given-names></name>
<name><surname>Smith</surname><given-names>L</given-names></name>
<name><surname>Gee</surname><given-names>SH</given-names></name><etal/>
</person-group> (<year>2012</year>) <article-title>Augmentation of clozapine with a second antipsychotic - a meta-analysis</article-title>. <source>Acta Psychiatr Scand</source> <volume>125</volume>: <fpage>15</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr84-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>DM</given-names></name>
<name><surname>Young</surname><given-names>C</given-names></name>
<name><surname>Paton</surname><given-names>C</given-names></name>
</person-group> (<year>2003</year>) <article-title>Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review</article-title>. <source>J Clin Psychiatry</source> <volume>64</volume>: <fpage>30</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr85-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
<name><surname>Lönnqvist</surname><given-names>J</given-names></name>
<name><surname>Wahlbeck</surname><given-names>K</given-names></name><etal/>
</person-group> (<year>2009</year>) <article-title>11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study)</article-title>. <source>Lancet</source> <volume>9690</volume>: <fpage>620</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr86-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tranulis</surname><given-names>C</given-names></name>
<name><surname>Skalli</surname><given-names>L</given-names></name>
<name><surname>Lalonde</surname><given-names>P</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Benefits and risks of antipsychotic polypharmacy: An evidence-based review of the literature</article-title>. <source>Drug Saf</source> <volume>31</volume>: <fpage>7</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr87-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Omori</surname><given-names>IM</given-names></name>
<name><surname>Fenton</surname><given-names>M</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Sulpiride augmentation for schizophrenia</article-title>. <source>Cochrane Database Syst Rev</source>. <fpage>CD008125</fpage>.</citation>
</ref>
<ref id="bibr88-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>CH</given-names></name>
<name><surname>Qin</surname><given-names>TE</given-names></name>
<name><surname>Lin</surname><given-names>YL</given-names></name><etal/>
</person-group> (<year>1994</year>) <article-title>A clinical effect and following-up study about sulpiride and clozapine for 105 cases of the schizophrenia type</article-title>. <source>J Xinxiang Med College</source> <volume>11</volume>: <fpage>148</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr89-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weiner</surname><given-names>E</given-names></name>
<name><surname>Conley</surname><given-names>RR</given-names></name>
<name><surname>Ball</surname><given-names>MP</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine</article-title>. <source>Neuropsychopharmacology</source> <volume>35</volume>: <fpage>2274</fpage>–<lpage>2283</lpage>.</citation>
</ref>
<ref id="bibr90-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinmann</surname><given-names>S</given-names></name>
<name><surname>Aderhold</surname><given-names>V</given-names></name>
</person-group> (<year>2010</year>) <article-title>Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses</article-title>. <source>Psychosis: Psychological, Social and Integrative Approaches</source> <volume>2</volume>: <fpage>50</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr91-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinmann</surname><given-names>S</given-names></name>
<name><surname>Hoerger</surname><given-names>S</given-names></name>
<name><surname>Erath</surname><given-names>M</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Implementation of a schizophrenia practice guideline: Clinical results</article-title>. <source>J Clin Psychiatry</source> <volume>69</volume>: <fpage>1299</fpage>–<lpage>1306</lpage>.</citation>
</ref>
<ref id="bibr92-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinmann</surname><given-names>S</given-names></name>
<name><surname>Read</surname><given-names>J</given-names></name>
<name><surname>Aderhold</surname><given-names>V</given-names></name>
</person-group> (<year>2009</year>) <article-title>Influence of antipsychotics on mortality in schizophrenia: Systematic review</article-title>. <source>Schizophr Res</source> <volume>113</volume>: <fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr93-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>I</given-names></name>
</person-group>. (<year>2002</year>) <article-title>A control study of risperidone and clozapine combination for treatment of refractory schizophrenia</article-title>. <source>Heath Psychol J</source> <volume>10</volume>: <fpage>135</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr94-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xao</surname><given-names>H</given-names></name>
</person-group> (<year>1999</year>) <article-title>A double-blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia</article-title>. <source>Sichuan Ment Health</source> <volume>12</volume>: <fpage>250</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr95-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xie</surname><given-names>C</given-names></name>
<name><surname>Ni</surname><given-names>XL</given-names></name>
</person-group> (<year>2001</year>) <article-title>The compared study of treating schizophrenia with risperidone combining clozapine</article-title>. <source>J Prev Med Inform</source> <volume>17</volume>: <fpage>245</fpage>.</citation>
</ref>
<ref id="bibr96-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xin</surname><given-names>X</given-names></name>
<name><surname>Du</surname><given-names>B</given-names></name>
<name><surname>Zeng</surname><given-names>Z</given-names></name>
</person-group> (<year>2001</year>) <article-title>A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia</article-title>. <source>Herald Med</source> <volume>20</volume>: <fpage>501</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr97-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>B</given-names></name>
</person-group> (<year>2006</year>) <article-title>Observation of the effect of clozapine and sulpiride on negative symptom schizophrenia patients</article-title>. <source>China Tropical Medicine</source> <volume>6</volume>: <fpage>806</fpage>.</citation>
</ref>
<ref id="bibr98-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yagi</surname><given-names>G</given-names></name>
</person-group> (<year>1976</year>) <article-title>A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients</article-title>. <source>Clin Eval</source> <volume>3</volume>: <fpage>351</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr99-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yue</surname><given-names>H</given-names></name>
<name><surname>Song</surname><given-names>L</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
</person-group> (<year>2004</year>) <article-title>A comparative trial of risperidone in the treatment of schizophrenia over two years</article-title>. <source>Shangai Arch Psychiatry</source> <volume>16</volume>: <fpage>165</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr100-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
</person-group> (<year>1989</year>) <article-title>A comparison study on the treatment effect of clozapine, chlorpromazine and the combination of clozapine and chlorpromazine in schizophrenia</article-title>. <source>Chin J Nerv Ment Dis</source> <volume>5</volume>: <fpage>306</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr101-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>B</given-names></name>
<name><surname>Ascher-Svanum</surname><given-names>H</given-names></name>
<name><surname>Faries</surname><given-names>DE</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Cost of antipsychotic polypharmacy in the treatment of schizophrenia</article-title>. <source>BMC Psychiatry</source> <volume>8</volume>: <fpage>19</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr102-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>H</given-names></name>
<name><surname>Deng</surname><given-names>D</given-names></name>
</person-group> (<year>2002</year>) <article-title>A study of clozapine combined with or without pipothiazine palmitate in refractory schizophrenia</article-title>. <source>J Clin Psychol Med</source> <volume>12</volume>: <fpage>15</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr103-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>D</given-names></name>
</person-group> (<year>1999</year>) <article-title>A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia</article-title>. <source>J Clin Psychol Med</source> <volume>9</volume>: <fpage>204</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr104-0269881113477709">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zou</surname><given-names>G</given-names></name>
<name><surname>Huang</surname><given-names>Y</given-names></name>
<name><surname>Zou</surname><given-names>S</given-names></name><etal/>
</person-group> (<year>2003</year>) <article-title>A comparative trial of the beneficial effects of sulpiride combined with clozapine in the treatment of refractory schizophrenia</article-title>. <source>J Yichun Univ</source> <volume>25</volume>: <fpage>94</fpage>–<lpage>96</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>